![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Effectiveness of DAA Regimens in Genotype 1 HIV/HCV Coinfected Patients:
An Analysis of the VA National Clinical Case Registry
|
|
|
Reported by Jules Levin
IDWeek Oct 26-30 2016
Debika Bhattacharya, MD, MS1,2, Pamela S. Belperio, PharmD3, Troy Shahoumian MPH, PhD3, Timothy P. Loomis PhD3, Matthew B. Goetz, MD1,2, Larry A. Mole, PharmD3 and Lisa I. Backus, MD, PhD3,4
1Department of Medicine, Veterans Affairs Greater Los Angeles Health Care System, Los Angeles, CA, USA 2 David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA 3Patient Care Services/Population Health,
Department of Veterans Affairs, Palo Alto Health Care System, Palo Alto, CA, USA 4 Department of Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA
![HCV1](../images/112816/112816-3/HCV1.gif)
![HCV2](../images/112816/112816-3/HCV2.gif)
![HCV3](../images/112816/112816-3/HCV3.gif)
![HCV4](../images/112816/112816-3/HCV4.gif)
![HCV5](../images/112816/112816-3/HCV5.gif)
![HCV6](../images/112816/112816-3/HCV6.gif)
![HCV7](../images/112816/112816-3/HCV7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|